The company's board has approved a proposal to buyback shares, subject to the approval of shareholders, for an aggregate of amount not exceeding Rs 1,569 crore, Dr Reddy's Laboratories said in a regulatory filing.
The drug maker said that the buyback is proposed on account of the Company’s strong cash flow position and is expected to be earning per share (EPS) accretive contributing to an overall enhancement of value of shareholders going forward.
"Based on the minimum buyback size and the maximum buyback price the company will purchase a minimum of 2.24 million shares," it added.
The company has appointed Kotak Mahindra Capital Company as its merchant banker for the buyback process.
At 11:36 AM, the stock was up 5.3% at Rs 3,118 on the NSE. A combined 705,373 shares changed hands on the counter on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)